The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.
Also called NCT02300233
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 114 participants
- Registry
-
NCT02300233 -
2014-003434-93
-
- Other papers using this trial's data
- Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, France, Germany, Netherlands, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02300233. Randomized; quadruple masking; primary purpose treatment. Start 2015-02-05 (actual); primary completion 2016-07-27 (actual). Results posted on 2022-04-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- Volanesorsen
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Collaborator
- Akcea Therapeutics
Record details
- Record id
cardio:ct-nct02300233- Content hash
d128cb0718bb79a836dab9f24dd63a1107e3ec8c79c0e193d080a6579b00ac92